Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
Commentary|Articles|May 7, 2026
ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
As conversations continue around the
Related to this article
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
Advertisement
Advertisement